Liver-Directed Molecular Therapies: Current and Upcoming Strategies

Area of Science:

• Hepatology
• Genetics
• Molecular Therapy

Background:

• Monogenic metabolic liver diseases are rare but collectively impact 1 in 800 live births.
• Liver transplantation is the primary cure for many of these debilitating genetic disorders.
• Advances in preclinical research are paving the way for clinical trials of novel molecular therapies.

Purpose of the Study:

• To review viral and nonviral vectors for targeted delivery of DNA and RNA therapies to the liver.
• To explore innovative gene editing techniques for treating monogenic liver diseases.
• To provide a concise overview of current and emerging therapeutic strategies.

Main Methods:

• Literature review of preclinical and clinical studies on gene therapy vectors.
• Analysis of gene editing technologies applicable to liver diseases.
• Synthesis of information on vector systems and delivery methods.

Main Results:

• Identification of various viral and nonviral vectors suitable for liver-targeted gene delivery.
• Overview of gene editing tools like CRISPR-Cas9 for correcting genetic defects.
• Highlighting the potential of molecular therapies as alternatives to transplantation.

Conclusions:

• Liver-targeted gene and RNA-based therapies show significant promise for treating monogenic liver diseases.
• Gene editing offers a precise approach to correct underlying genetic mutations.
• Further development and clinical translation of these therapies are crucial.